Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Novo Nordisk advanced amycretin, a GLP-1/amylin receptor agonist, straight to Phase 3 after early results showed weight reductions up to 24.3%
Its a mix of historical precedent, cost, and risk management
This is a significant shift from the higher costs often associated with injectable GLP-1s, aiming to make the treatment more accessible to a broader population
In total, the company expects an estimated negative impact of 6 percentage points on full-year operating profit growth at CER in 2025, compared to the 10-16% at CER estimated on Aug
These findings are hugely encouraging, said Professor Newsome
If you are a postmenopausal woman starting semaglutide and have any history of UTIs, discuss vaginal estrogen with your healthcare provider before UTIs become a recurring problem
US$ 28.31
US$ 22.87
US$ 27.54
US$ 25.61
US$ 23.48
US$ 26.63
US$ 21.49
US$ 25.57
